Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF +20.96%65 Earnings per Share (Diluted) is $0.02 as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $8.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 789 Drug Manufacturers companies, CanSino Biologics ranks worse than 126742.59% on this metric.
CanSino Biologics's EPS (Basic) for the
three
months ended in Dec. 2025 was $0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
During the past 10 years, CanSino Biologics's highest 3-Year average EPS without NRI Growth Rate was -44.60% per year. The lowest was -75.40% per year. And the median was -60.20% per year.
CanSino Biologics (OTCPK:CASBF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
CanSino Biologics Earnings per Share (Diluted) Related Terms
CanSino Biologics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics Earnings per Share (Diluted) Chart
CASBF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's PE Ratio distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's PE Ratio falls into.
CanSino Biologics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
CanSino Biologics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.02 mean?
CanSino Biologics (CASBF) has a Earnings per Share (Diluted) of $0.02 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #999999 out of 789 companies in the Drug Manufacturers industry.
Is CanSino Biologics' Earnings per Share (Diluted) too high?
CanSino Biologics' current Earnings per Share (Diluted) is $0.02. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.60. CanSino Biologics' value of $0.02 is 99.8% below this industry median. Based on the distribution chart, CanSino Biologics ranks #999999 out of 789 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #999999 out of 789 companies for Earnings per Share (Diluted). This places CanSino Biologics in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.60. CanSino Biologics' value of $0.02 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Earnings per Share (Diluted) of $0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Earnings per Share (Diluted) is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.85, compared to a current price of $3.15 — trading 64.5% below its estimated fair value. The current Earnings per Share (Diluted) is $0.02 and 99.8% below the Drug Manufacturers industry median of 9.60. CanSino Biologics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Earnings per Share (Diluted) is $0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $3.15 is trading 64.5% below its estimated GF Value™ of $8.85.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Earnings per Share (Diluted): $0.02
GF Value™: $8.85 vs. price of $3.15 (64.5% below fair value)
Industry Position: 99.8% below the Drug Manufacturers median (#999999 of 789)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score
Get the complete analysis for CASBF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
